Navigating the complexities of Benefit–Risk Assessments (BRA) is essential to ensuring the safety and efficacy of medicinal products throughout their lifecycle. Regulatory decision-making demands transparency, collaboration, and structured methodologies to address uncertainties and prioritise patient-centric outcomes.
This article explores current and emerging BRA methodologies, highlighting frameworks such as PrOACT-URL (problem, objectives, alternatives, consequences, trade-off, uncertainty, risk tolerance, and linked decisions), Benefit–Risk Action Team (BRAT), and Consortium on Benefit–Risk Assessment (COBRA), as well as the Council for International Organizations of Medical Sciences (CIOMS) Working Group XII report. It introduces the concept of lifecycle-based assessment and the Benefit–Risk Assessment Document (BRAD) as a living tool for proactive planning and effective communication.
Gain insights into improving BRA processes by incorporating patient perspectives, innovative study designs, and dynamic visualisations that promote transparency and stakeholder collaboration.